PrEP (pre-exposure prophylaxis) is a new HIV prevention intervention. PrEP Watch is a clearinghouse for PrEP data, additional research, cost, access and advocacy efforts across the globe.
Communities across the globe are at varying stages of implementation of daily oral PrEP. TDF/FTC is approved for use as oral PrEP in a handful of countries, and access is expanding globally. In some places there is growing uptake; in others, access is limited to pilot projects. Other countries are not yet exploring implementation. Learn more about access and advocacy below.
Daily oral PrEP involves drugs that are also used in HIV treatment. This means the strategy may only be available via off-label use in some places. Much work is needed to see innovative, impactful introduction.
April 19, 2016
The NHS in England is to reconsider its controversial decision not to provide Truvada for HIV prevention.
April 4, 2016
James Krellenstein and Jeremiah Johnson write in the April issue of TAGline about the high cost of PrEP as a deterrent to increased uptake. They discuss problems with Gilead’s medical and co-pay assistance program (MAP/CAP), the company’s reluctance to prioritize PrEP and how Gilead is “profiting from its PrEP monopoly”. The article ends with recommendations for Gilead which include increasing CAP contribution and aggressively promoting CAP and MAP.
March 24, 2016
AVAC's Policy Director Kevin Fisher reports on a visit to a PrEP project underway in Senegal. This is the first in a planned P-Values series on PrEP in action.
March 22, 2016